IFPA GRAPPA Guidelines Awareness Campaign Question Title * 1. It is important for your patients to feel comfortable discussing any health-associated conditions they have with their healthcare provider. Do you discuss psoriatic arthritis comorbidities with your patients? Yes No Sometimes Question Title * 2. Are you open to screening or asking your patient about comorbidities that may have an impact on the type of therapy approach used? (Examples of comorbidities include mental health issues and metabolic syndrome). Yes No Question Title * 3. Do you discuss the overarching aims of treatment and treatment goals with your patients? Yes No Question Title * 4. Do you discuss the various treatment guidelines used for treating psoriatic arthritis with your patients? Yes No Question Title * 5. What is your understanding of the treatment guidelines for psoriatic arthritis? I have a clear understanding I have a general understanding but would like more information I am not sure what the treatment guidelines are Question Title * 6. How important do you think it is to follow the treatment guidelines to treat psoriatic arthritis? Extremely important Somewhat important Not so important Question Title * 7. Are you aware of the recent updates to the GRAPPA treatment recommendations for patients with psoriatic arthritis? Yes No Question Title * 8. Following a period of low/no disease activity, a patient with psoriatic arthritis presents with axial symptoms and dactylitis despite treatment with NSAIDs, physiotherapy, and glucocorticoids. The patient also has Crohn’s disease, but no evidence of other autoimmune diseases or heart disease, and no previous malignancy. Which would be the most appropriate next treatment step according to the updated GRAPPA guidelines? An IL-17 inhibitor, such as secukinumab or brodalumab An IL-23 inhibitor, such as guselkumab or risankizumab A TNF inhibitor, such as adalimumab or infliximab Question Title * 9. On a scale of 1 (never) to 5 (always), how often do you currently follow the updated GRAPPA treatment guidelines when recommending treatments to your patients with psoriatic arthritis? 1 5 Clear i We adjusted the number you entered based on the slider’s scale. Done